rnaset2 Antibody

What is RNASET2 and why is it significant in research contexts?

RNASET2 (Ribonuclease T2) is a protein belonging to the RNase T2 family with a molecular weight of approximately 29 kDa. It plays essential roles in innate immune response by recognizing and degrading RNAs from microbial pathogens that are subsequently sensed by TLR8. RNASET2 has been implicated in multiple disease processes, functioning as a tumor suppressor in some cancers while displaying oncogenic properties in others. The protein has gained research importance due to its associations with autoimmune diseases like Crohn's disease and its potential as both a biomarker and therapeutic target. RNASET2 is also known by alternative names including RNASE6PL (Ribonuclease 6) and is ubiquitously expressed across many tissue types. The protein undergoes post-translational modifications, including glycosylation, which may affect its function and detection in experimental systems .

What are the optimal applications and dilution ratios for RNASET2 antibodies?

RNASET2 antibodies can be utilized in multiple experimental applications with specific recommended dilutions:

It is critical to titrate these reagents in each testing system to obtain optimal results, as experimental conditions and sample types can significantly influence antibody performance. When establishing a new protocol, researchers should begin with the manufacturer's recommended dilutions and adjust as needed based on signal-to-noise ratio .

Which tissue and cell types have validated reactivity with RNASET2 antibodies?

RNASET2 antibodies have demonstrated confirmed reactivity with human, mouse, and rat samples. Specific positive controls include:

• Positive IP detection in BxPC-3 cells (pancreatic cancer cell line)

• Positive IHC detection in mouse spleen tissue

• Positive IF/ICC detection in transfected cells

These experimentally verified samples provide reliable positive controls for antibody validation and optimization. When establishing new protocols, researchers should prioritize these validated systems before extending to other experimental models .

What antigen retrieval methods are recommended for RNASET2 immunohistochemistry?

For optimal RNASET2 detection in immunohistochemical applications, the following antigen retrieval methods are recommended:

• Primary recommendation: TE buffer at pH 9.0

• Alternative method: Citrate buffer at pH 6.0

These conditions help expose epitopes that may be masked during fixation procedures, enabling more effective antibody binding and signal detection. The optimal method may vary depending on tissue type, fixation process, and specific antibody clone, requiring method validation for each experimental system .

How can RNASET2 antibodies contribute to autoimmune disease research?

RNASET2 variants have been associated with risk for several autoimmune diseases, particularly Crohn's disease (CD), through genome-wide association studies. When investigating RNASET2 in this context, researchers can apply antibody-based approaches to:

• Quantify circulating RNASET2 protein levels in patient serum as a potential biomarker

• Monitor protein expression changes in response to inflammatory stimuli and treatments

• Examine the relationship between genetic variants and protein expression through allele-specific detection methods

• Evaluate RNASET2's role in modulating T-cell activation and inflammatory responses

Research has demonstrated that CD patients with severe disease necessitating surgical intervention show decreased preoperative circulating RNASET2 protein levels compared to non-IBD subjects. These levels rebound post-operatively following removal of inflamed intestinal tissue, with levels associated with specific allelic carriage. This suggests RNASET2 protein levels may serve as both a biomarker and potential therapeutic target in inflammatory bowel disease .

What experimental approaches can assess RNASET2's role in cancer pathobiology?

In cancer research, particularly clear cell renal cell carcinoma (ccRCC) where RNASET2 is upregulated, antibody-based approaches can be implemented to:

• Compare protein expression between tumor and adjacent normal tissues using immunohistochemistry

• Evaluate subcellular localization using immunofluorescence microscopy

• Correlate expression levels with clinical outcomes and prognostic indicators

• Analyze the relationship between RNASET2 expression and tumor microenvironment characteristics

Recent studies have shown that RNASET2 expression is significantly upregulated in ccRCC tissues compared to normal controls and correlates with poor prognosis. Functional experiments involving RNASET2 silencing demonstrate that it may promote migration and angiogenesis in renal cancer cells, suggesting oncogenic properties in this specific cancer context .

How can researchers investigate relationships between RNASET2 and immune cell infiltration?

To examine RNASET2's role in immune microenvironment modulation, researchers can:

• Perform dual immunohistochemical staining for RNASET2 and immune cell markers (e.g., Foxp3 for regulatory T cells)

• Quantify correlations between RNASET2 expression and immune cell populations

• Analyze the impact of RNASET2 expression levels on different immune cell subsets

• Evaluate how RNASET2 genetic variants affect immune cell recruitment and function

Immunohistochemical analyses have demonstrated that RNASET2 expression positively correlates with regulatory T cell (Treg) infiltration in ccRCC. Higher RNASET2 expression is associated with increased Treg infiltration, which in turn correlates with poor outcomes in ccRCC patients. This suggests that RNASET2 may influence cancer progression partly through immunomodulatory effects on the tumor microenvironment .

What is the potential therapeutic relevance of RNASET2 manipulation?

RNASET2 shows promising therapeutic potential that can be investigated through antibody-based detection methods:

• Monitoring changes in RNASET2 expression following experimental treatments

• Evaluating the effects of recombinant RNASET2 administration on inflammatory responses

• Assessing how RNASET2 overexpression affects cytokine production and immune cell function

• Developing RNASET2-targeted interventions for inflammatory conditions or cancer

Research has demonstrated that both RNASET2 overexpression and treatment with recombinant RNASET2 protein can significantly reduce TL1A-mediated IFN-γ secretion in CD4+ T cells. This effect occurs in a dose-dependent manner, with as little as 4ng/ml of recombinant RNASET2 inducing a 30% reduction in IFN-γ secretion. These findings suggest that RNASET2 supplementation could represent a novel therapeutic approach for inflammatory conditions characterized by dysregulated cytokine production .

What are critical storage and handling requirements for RNASET2 antibodies?

Proper storage and handling are essential for maintaining antibody performance:

Following these guidelines ensures optimal antibody stability and performance. Repeated freeze-thaw cycles should be avoided, and antibodies should be handled on ice during experimental procedures to prevent degradation .

How can researchers troubleshoot non-specific binding in RNASET2 immunodetection?

When encountering non-specific binding:

• Optimize blocking conditions: Use appropriate blocking agents (BSA, normal serum, commercial blockers) matched to the host species of the secondary antibody

• Adjust antibody dilutions: Titrate primary antibody concentrations to identify optimal signal-to-noise ratio

• Modify washing protocols: Increase washing duration or detergent concentration to reduce background

• Validate antibody specificity: Use RNASET2 knockdown/knockout controls to confirm signal specificity

• Examine cross-reactivity: Test antibody reactivity on tissues known to lack RNASET2 expression

Each application (IHC, IF, WB) may require different optimization strategies to minimize background while maintaining specific signal detection .

How should researchers interpret discrepancies between RNASET2 mRNA and protein expression?

When analyzing inconsistencies between mRNA and protein data:

• Consider temporal dynamics: RNASET2 mRNA expression decreases in response to T-cell activation and recovers following elimination of the activator

• Evaluate post-transcriptional regulation: Disease risk variants affect both transcriptional and post-transcriptional mechanisms

• Assess allelic imbalance: Specific RNASET2 variants (e.g., rs2149092) demonstrate allelic imbalance affecting transcription factor binding and promoter transactivation

• Examine protein stability factors: Post-translational modifications may affect protein half-life independently of transcription rates

Comprehensive analysis should include both mRNA and protein detection methods with appropriate time-course designs to capture the dynamic regulation of RNASET2 expression .

What controls are essential for valid interpretation of RNASET2 antibody experiments?

Essential controls include:

• Positive tissue controls: Mouse spleen tissue for IHC applications

• Positive cell line controls: BxPC-3 cells for immunoprecipitation

• Negative controls: Samples without primary antibody application

• Isotype controls: Matched isotype immunoglobulins to assess non-specific binding

• Expression validation controls: Cells transfected with RNASET2 expression constructs or siRNA

Implementing these controls ensures experimental reliability and facilitates accurate interpretation of results across different applications and experimental systems .

How can RNASET2 antibodies help resolve the protein's seemingly contradictory roles in different cancers?

RNASET2 exhibits context-dependent functions, acting as a tumor suppressor in some cancers while demonstrating oncogenic properties in others. To investigate this duality:

• Compare expression patterns and subcellular localization across multiple cancer types

• Correlate expression with specific tumor microenvironment characteristics

• Examine protein-protein interactions in different cellular contexts

• Analyze post-translational modifications that may alter protein function

While RNASET2 has been reported to behave as a class II tumor suppressor in ovarian cancer, recent studies demonstrate upregulation and oncogenic functions in ccRCC. Antibody-based detection methods can help elucidate the molecular mechanisms underlying these divergent roles .

What emerging technologies might enhance RNASET2 antibody-based research?

Advanced techniques that can augment RNASET2 research include:

• Multiplexed immunofluorescence to simultaneously examine RNASET2 and other markers

• Single-cell protein analysis to assess expression heterogeneity

• Proximity ligation assays to identify protein-protein interactions

• Mass spectrometry-based proteomics to characterize post-translational modifications

• CRISPR-based functional genomics combined with antibody detection

These approaches can provide deeper insights into RNASET2 regulation and function across different cellular contexts and disease states, potentially revealing new therapeutic opportunities .

How might genetic variation in RNASET2 impact antibody-based detection methods?

Genetic variants in RNASET2 can affect antibody-based detection in several ways:

• Epitope alterations: Variants may modify antibody binding sites, affecting detection efficiency

• Expression level changes: Risk variants associated with decreased expression may require more sensitive detection methods

• Alternative splicing: RNASET2 has two reported isoforms, and variants may affect isoform ratios

• Post-translational modifications: Variants can alter glycosylation and other modifications that influence antibody recognition

When designing studies, researchers should consider genotyping samples and selecting antibodies that target conserved regions not affected by common variants. Transcriptome sequencing of RNASET2 knockdown cells can help identify variant-specific effects on gene expression and downstream pathways .

What is the potential for developing RNASET2-based therapeutic strategies?

RNASET2-targeted therapeutics show promise for inflammatory conditions and potentially certain cancers:

• Recombinant RNASET2 therapy: Direct administration to attenuate inflammatory responses

• RNASET2 expression modulators: Compounds that increase expression in contexts where it's protective

• Targeted inhibition: Blocking RNASET2 in contexts where it promotes disease (e.g., ccRCC)

• Biomarker application: Monitoring RNASET2 levels to assess treatment response

Experimental evidence demonstrates that recombinant RNASET2 protein can directly modify inflammatory responses, with dose-dependent attenuation of IFN-γ secretion in both healthy donor cells and those isolated from inflammatory bowel disease patients. This suggests potential applications in treating inflammatory conditions where cytokine dysregulation plays a central role .

What criteria should guide antibody selection for specific RNASET2 research applications?

When selecting RNASET2 antibodies, researchers should consider:

• Application compatibility: Verify validation for intended applications (WB, IHC, IF, IP)

• Species reactivity: Confirm reactivity with target species (human, mouse, rat)

• Epitope location: Select antibodies targeting conserved regions for cross-species studies

• Validation data: Review published evidence and manufacturer validation

• Clone type: Consider monoclonal for specificity or polyclonal for broader epitope recognition

The available data indicate that rabbit polyclonal antibodies against RNASET2 have been successfully validated for multiple applications including IP, IHC, and IF/ICC across human, mouse, and rat samples .

How do different fixation and preparation methods affect RNASET2 antibody performance?

Sample preparation significantly impacts antibody performance:

• Fixation effects: Formalin fixation may mask epitopes requiring specific retrieval methods

• Antigen retrieval: TE buffer (pH 9.0) is recommended, with citrate buffer (pH 6.0) as an alternative

• Blocking optimization: 0.1% BSA inclusion improves signal-to-noise ratio in some applications

• Tissue-specific considerations: Different tissues may require adjusted protocols